Quantcast

Latest Regenerative medicine Stories

2014-05-22 23:09:01

Patients now have the opportunity to receive Regenerative Medicine services at Healthpointe. La Mirada, CA (PRWEB) May 22, 2014 Healthpointe Medical Group is proud to announce that they are offering Regenerative Medicine Services at their facilities located throughout Southern California. Regenerative Medicine is a rapidly growing field that is aimed at restoring and/or replenishing the normal function of tissues that are damaged or otherwise affected by diseases. Through this program,...

2014-05-16 08:27:03

/PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) CEO and President, Richard Garr, will present at the World Stem Cells & Regenerative Medicine Congress, on Thursday, May 22, at 11:35 a.m. BST in London, UK (http://www.terrapinn.com/conference/stem-cells/index.stm). Neuralstem is currently in a Phase II clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) with its NSI-566 stem cells and has been approved to commence a Phase I study in spinal cord...

2014-05-14 12:31:15

LONDON, May 14, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Biopreservation Market (Product Types - Equipment, LIMS, and Media; Applications - Regenerative Medicine, Biobanking, and Drug Discovery) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 -...

2014-05-13 12:34:16

NEW YORK, May 13, 2014 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that Merril Hoge, former star NFL player and an on-air analyst for ESPN, has joined its Board of Advisors. According to Merril Hoge, "After tearing a ligament in my elbow I tried to rehab it to avoid...

2014-05-12 08:33:28

ROCKVILLE, Md., May 12, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended March 31, 2014 and provided a business and clinical update. "During the first quarter of 2014, we continued to advance the NSI-566 cell therapy platform through human clinical trials. We have completed treatment of the fourth cohort in our ALS Phase II escalating dose trials, in collaboration with our sites at University of Michigan, Emory and...

2014-05-12 08:33:04

SAN DIEGO, May 12, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced that the Company's Excellagen(®) flowable dermal matrix in combination with Orbsen Therapeutics' mesenchymal stromal stem cell therapy Cyndacel-M(TM) has been selected for clinical evaluation in a Phase 1b safety study for the potential treatment of chronic diabetic wounds to be funded by the European Union under EU Framework 7 (FP7). The project, known by the...

2014-05-08 12:30:08

Two new gifts will benefit faculty in stem cell science and digestive diseases LOS ANGELES, May 8, 2014 /PRNewswire-USNewswire/ -- Two new gifts from The Eli and Edythe Broad Foundation to UCLA totaling $4 million will fund research in stem cell science and digestive diseases and support the recruitment of key faculty at two renowned research centers. The gifts bring to $30 million The Broad Foundation's total support of faculty recruitment and basic and translational research at...

2014-05-07 12:29:37

NEW YORK, May 7, 2014 /PRNewswire/ -- IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has received a final positive ruling in its case against Ironridge Global IV, LTD. ("Ironridge"), and TCA Global Credit Master Fund, LP ("TCA"). On May 5, 2014 Judge Jeffrey K. Oing "ORDERED that the motion by...

2014-05-06 08:36:03

CLEVELAND, May 6, 2014 /PRNewswire-USNewswire/ -- Juventas Therapeutics today announced that top-line interim data from its ongoing Phase II STOP-HF study will be presented in a late-breaking oral presentation at the European Society of Cardiology Heart Failure Congress (ESC-HF) taking place May 17 - 20, 2014 in Athens, Greece. The STOP-HF trial is a randomized, placebo-controlled, double-blinded study conducted at 15 centers in the United States to evaluate safety and efficacy of...

2014-05-05 23:06:09

A new study released today in STEM CELLS Translational Medicine demonstrates the regenerative effects of mesenchymal stem cells (MSC) on the anal sphincter. The work could have implications for the 11 percent of the population suffering fecal incontinence due to an injury or disease. Durham, NC (PRWEB) May 05, 2014 A new study released today in STEM CELLS Translational Medicine demonstrates the regenerative effects of mesenchymal stem cells (MSC) on the anal sphincter. The work could have...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'